The Disparate Effects of Epinephrine and Norepinephrine on Hyperglycemia in Cardiovascular Surgery
DOI:
https://doi.org/10.1532/hsf.2008Abstract
Hyperglycemia is a metabolic derangement that frequently develops after cardiovascular surgery. The perioperative administration of inotropic and vasoactive agents, such as epinephrine and norepinephrine, are common in the management of cardiac surgery patients and are known to contribute to the development of postoperative hyperglycemia. We hypothesized that hemodynamic support with epinephrine exacerbates postoperative hyperglycemia to a greater degree than does treatment with norepinephrine. This literature review outlines the mechanisms by which epinephrine and norepinephrine alter glucose homeostasis, while highlighting the significant differences in their effects on hepatic glucose mobilization and peripheral glucose utilization. This review suggests that the use of epinephrine exacerbates postoperative hyperglycemia to a greater degree than does norepinephrine.
References
Abel JJ, Crawford AC. 1897. On the blood-pressure-raising constituent of the suprarenal capsule. Bull Johns Hopkins Hosp 8:151-7.
Antonis A, Clark ML, Hodge RL, Molony M, Pilkington TR. 1967. Receptor mechanisms in the hyperglycaemic response to adrenaline in man. Lancet 1(7500):1135-7.
Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Rydén L. 2004. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 25(22):1990-7.
Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyorala K, Simoons M, et al. 2004. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe: the Euro Heart Survey on diabetes and the heart. Eur Heart J 25(21):1880-90.
Biggers DW, Myers SR, Neal D, et al. 1989. Role of brain in counterregulation of insulin-induced hypoglycemia in dogs. Diabetes 38(1):7-16.
Connolly CC, Steiner KE, Stevenson RW, et al. 1991. Regulation of glucose metabolism by norepinephrine in conscious dogs. Am J Physiol 261(6 Pt 1):E764-72.
Cryer PE. 1980. Physiology and pathophysiology of the human sympathoadrenal neuroendocrine system. N Engl J Med 303(8):436-44.
Deibert DC, DeFronzo RA. 1980. Epinephrine-induced insulin resistance in man. J Clin Invest 65(3):717-21.
Dufour S, Lebon V, Shulman GI, Petersen KF. 2009. Regulation of net hepatic glycogenolysis and gluconeogenesis by epinephrine in humans. Am J Physiol Endocrinol Metab 297(1):E231-5.
Ebner S, Burnol AF, Ferre P, de Saintaurin MA, Girard J. 1987. Effects of insulin and norepinephrine on glucose transport and metabolism in rat brown adipocytes: potentiation by insulin of norepinephrine-induced glucose oxidation. Eur J Biochem 170(1-2):469-74.
Edwards AV, Silver M. 1972. Comparison of the hyperglycaemic and glycogenolytic responses to catecholamines with those to stimulation of the hepatic sympathetic innervation in the dog. J Physiol 223(2):571-93.
Eigler N, Saccà L, Sherwin RS. 1979. Synergistic interactions of physiologic increments of glucagon, epinephrine, and cortisol in the dog: a model for stress-induced hyperglycemia. J Clin Invest 63(1):114-23.
Furnary AP, Gao G, Grunkemeier GL, et al. 2003. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 125(5):1007-21.
Gerich JE. 1988. Glucose counterregulation and its impact on diabetes mellitus. Diabetes 37(12):1608-17. Lilly Lecture 1988.
Gerstein HC, Miller ME, Ismail-Beigi F, et al. 2014. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet 384(9958):1936-41.
Girish G, Agarwal S, Satsangi DK, Tempe D, Dutta N, Pratap H. 2014. Glycemic control in cardiac surgery: rationale and current evidence. Ann Card Anaesth 17(3):222-8.
Hatmann H, Beckh H, Jungermann K. 1982. Direct control of glycogen metabolism in the perfused rat liver by the sympathetic innervation. Eur J Biochem 123(3):521-6.
Hjemdahl P, Belfrage E, Daleskog M. 1979. Vascular and metabolic effects of circulating epinephrine and norepinephrine: concentration-effect study in dogs. J Clin Invest 64(5):1221-8.
Ito N, Iwaya T, Ikeda K, et al. 2014. Hyperglycemia 3 days after esophageal cancer surgery is associated with an increased risk of postoperative infection. J Gastrointest Surg 18(9):1547-56.
Kvetnansky R, Sabban EL, Palkovits M. 2009. Catecholaminergic systems in stress: structural and molecular genetic approaches. Physiol Rev 89(2):535-606.
Lautt WW. 1983. Afferent and efferent neural roles in liver function. Prog Neurobiol 21(4):323-48.
Marette A, Bukowiecki LJ. 1989. Stimulation of glucose transport by insulin and norepinephrine in isolated rat brown adipocytes. Am J Physiol 257(4 Pt 1):C714-21.
McGuinness OP, Shau V, Benson EM, et al. 1997. Role of epinephrine and norepinephrine in the metabolic response to stress hormone infusion in the conscious dog. Am J Physiol 273(4 Pt 1) :E674-81.
Mulla I, Schmidt K, Cashy J, et al. 2014. Comparison of glycemic and surgical outcomes after change in glycemic targets in cardiac surgery patients. Diabetes Care 37(11): 2960-5.
Nobin A, Falck B, Ingemansson S, Järhult J, Rosengren E. 1977. Organization and function of the sympathetic innervation. Acta Physiol Scand Suppl 452:103-6.
Oliver G, Schäfer EA. 1895. The physiological effects of extracts of the suprarenal capsules. J Physiol 18(3):230-76
Reddy P, Duggar B, Butterworth J. 2014. Blood glucose management in the patient undergoing cardiac surgery: A review. World J Cardiol 6(11):1209-17.
Rui L. 2014. Energy metabolism in the liver. Compr Physiol 4(1):177-97.
Sacca L, Sherwin R, Felig P. 1978. Effect of sequential infusions of glucagon and epinephrine on glucose turnover in the dog. Am J Physiol 235(3):E287-90.
Sherwin RS, Sacca L. 1984. Effect of epinephrine on glucose metabolism in humans: contribution of the liver. Am J Physiol 247(2 Pt 1):E157-65.
Stevenson RW, Steiner KE, Connolly CC, et al. 1991. Dose-related effects of epinephrine on glucose production in conscious dogs. Am J Physiol 260(3 Pt 1):E363-70.
Takamine J. 1901. The isolation of the active principle of the suprarenal gland. J Physiol 27:29P-30P.
von Euler US. 1946. A specific sympathomimetic ergone in adrenergic nerve fibres (sympathin) and its relations to adrenaline and nor-adrenaline. Acta Physiol Scand 12(1):73-97.
Walaas O, Walaas E. 1950. Effect of epinephrine on rat diaphragm. J Biol Chem 187(2):769-76.
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).
